Suppr超能文献

第一代 H1 抗组胺药的风险:GA2LEN 立场文件。

Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper.

机构信息

Department of Dermatology and Allergy, Charité- Universitätsmedizin Berlin, Germany.

出版信息

Allergy. 2010 Apr;65(4):459-66. doi: 10.1111/j.1398-9995.2009.02325.x. Epub 2010 Feb 8.

Abstract

BACKGROUND

First-generation H(1)-antihistamines obtained without prescription are the most frequent form of self-medication for allergic diseases, coughs and colds and insomnia even though they have potentially dangerous unwanted effects which are not recognized by the general public.

AIMS

To increase consumer protection by bringing to the attention of regulatory authorities, physicians and the general public the potential dangers of the indiscriminate use first-generation H(1)-antihistamines purchased over-the counter in the absence of appropriate medical supervision.

METHODS

A GA(2)LEN (Global Allergy and Asthma European Network) task force assessed the unwanted side-effects and potential dangers of first-generation H1-antihistamines by reviewing the literature (Medline and Embase) and performing a media audit of US coverage from 1996 to 2008 of accidents and fatal adverse events in which these drugs were implicated.

RESULTS

First-generation H(1)-antihistamines, all of which are sedating, are generally regarded as safe by laypersons and healthcare professionals because of their long-standing use. However, they reduce rapid eye movement (REM)-sleep, impair learning and reduce work efficiency. They are implicated in civil aviation, motor vehicle and boating accidents, deaths as a result of accidental or intentional overdosing in infants and young children and suicide in teenagers and adults. Some exhibit cardiotoxicity in overdose.

CONCLUSIONS

This review raises the issue of better consumer protection by recommending that older first-generation H(1)-antihistamines should no longer be available over-the-counter as prescription- free drugs for self-medication of allergic and other diseases now that newer second- generation nonsedating H(1)-antihistamines with superior risk/benefit ratios are widely available at competitive prices.

摘要

背景

第一代 H(1)-抗组胺药无需处方即可获得,是治疗过敏疾病、咳嗽、感冒和失眠的最常见自我用药形式,尽管它们具有潜在的危险且不为公众所认知的不良反应。

目的

通过引起监管机构、医生和公众对未经适当医疗监督而滥用第一代 H(1)-抗组胺药的潜在危险的关注,从而提高消费者保护。

方法

GA(2)LEN(全球过敏和哮喘欧洲网络)工作组通过审查文献(Medline 和 Embase)并对 1996 年至 2008 年美国媒体对这些药物相关的事故和致命不良事件的报道进行媒体审计,评估第一代 H1-抗组胺药的不良副作用和潜在危险。

结果

第一代 H(1)-抗组胺药均具有镇静作用,由于其长期使用,一般被非专业人士和医疗保健专业人员认为是安全的。然而,它们会减少快速眼动(REM)睡眠,损害学习和降低工作效率。它们与民航、机动车和船只事故有关,还与婴儿和幼儿意外或故意过量用药以及青少年和成年人自杀有关。一些药物在过量使用时会表现出心脏毒性。

结论

本综述提出了更好的消费者保护问题,建议不再将旧的第一代 H(1)-抗组胺药作为无处方的自我用药,用于治疗过敏和其他疾病,因为现在有广泛的、价格具有竞争力的新型第二代非镇静 H(1)-抗组胺药,具有更好的风险/效益比。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验